Trial · NCT05265975
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
NCT05265975, Phase 1, Phase 2, Terminated, Antengene Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL. Trials, record NCT05265975. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05265975
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
- NCT number
- NCT05265975
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 54 participants, actual
- Lead sponsor
- Antengene Corporation
- Conditions
- Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
- Interventions
- ATG-010, Lenalidomide, Rituximab
- First posted
- 2022-03-04
- Last updated
- 2025-06-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DLT | 28 days after administration | The occurrence of severe toxicities during the first cycle of systemic cancer therapy |
| Primary | AE | 28 days after administration | Any adverse medical event that occurs after a patient or clinical trial subject receives a drug product, but is not necessarily related to the treatment. |
| Secondary | ORR | One year after last patient first dose | Percentage of subjects with PR, or CR |
| Secondary | PFS | One year after last patient first dose | Duration of time from the first dose of study drug until progression or death due to any cause |
| Secondary | DOR | One year after last patient first dose | Duration of time from first occurrence of CR or PR until the first date that disease |
| Secondary | OS | One year after last patient first dose | Duration of time from the first dose of study drug until death due to any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05265975
GET https://conductscience.org/api/trials/v1/NCT05265975/registered